Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Randomized, Double Blind, Active And Placebo Controlled Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1MG BID And Bupropion Hydrochloride 150MG BID For Smoking Cessation In Subjects With And Without A History of Psychiatric Disorders

Next Previous
Trial Profile

A Phase 4, Randomized, Double Blind, Active And Placebo Controlled Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks Varenicline Tartrate 1MG BID And Bupropion Hydrochloride 150MG BID For Smoking Cessation In Subjects With And Without A History of Psychiatric Disorders

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion (Primary) ; Varenicline (Primary) ; Nicotine replacement therapy
  • Indications Smoking withdrawal
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EAGLES
  • Sponsors Pfizer

    • Most Recent Events

    • 01 May 2022 Results assessing effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression published in the Depression and Anxiety
    • 03 Nov 2020 Results of post-hoc subgroup analysis assessing EAGLES safety and efficacy outcomes identical to the parent trial, published in the Psychiatric Services
    • 01 Mar 2019 Results of a secondary analysis assessing the safety and efficacy outcomes by psychiatric diagnosis (n=4092), published in the Journal of Clinical Psychopharmacology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top